Pre-Bell Check In: (SHPH) Surpasses Key Technical Levels On Approx. 35% Move

*Sponsored Just In: Jeff Ackerman Initiates Coverage on (SHPH)! Here’s What We Can Tell You—Right Now… Fewer Than 3.5M Shares In Circulation Puts (SHPH) In Ultra-Low Float Territory. A Recent Approx. 57% Move From $0.3501 To $0.55 In Just Six Sessions Shows How Quickly (SHPH) Can React. Projected Growth To $5.68B In The Glioblastoma Space Aligns With (SHPH)’s Current Direction. Recent Progress In A Phase 2 Trial Positions (SHPH) In A High-Need  Area Of Oncology. Pipeline Projects At (SHPH) Include Immune-Enhancing Therapies And  Advanced Diagnostics. Operating In One Of The Fastest-Growing Biotechnology Corridors In The Country—(SHPH) Has Local Access To Key Federal And  Scientific Resources. April 11, 2025 Dear Reader, Have you got (SHPH) on your screen yet? The bell rings in about 15 minutes. (SHPH) surpassed several key moving averages on its approximately 35% overnight move from $.40 to $.54 this morning’s early session, including its 5-Day, 20-Day, and 50-Day. Just after yesterday's closing bell, Shuttle Pharmaceuticals (Nasdaq: SHPH) dropped a late-breaking update that could reshape its role in prostate cancer treatment.  The company filed a provisional patent application with the USPTO titled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.” Developed alongside renowned medicinal chemist Dr. Alan Kozikowski—whose work contributed to Pylarify® and Pluvicto®—the new molecule is designed to selectively enhance radiation and chemotherapy effects in PSMA-expressing tumors. The filing strengthens SHPH’s diagnostics strategy, which includes PC-RAD and PSMA-B, and positions the company inside a market expected to reach $2B in PSMA-targeted treatments.  Momentum may just be getting started.  If you missed my earlier coverage on (SHPH) keep reading to get up to speed. Tucked inside Gaithersburg, Maryland—one of the fastest-growing biotechnology corridors in the country—is a name few have heard of, but many may start noticing soon. This quiet pocket of Maryland is no ordinary zip code.  It’s home to over 200 biotech firms and sits just miles from two of the world’s most influential medical authorities: the NIH and the FDA.  The environment here is built for breakthroughs—and one little-known company is beginning to show exactly why it planted roots here. Shuttle Pharmaceuticals (Nasdaq: SHPH) just made its way to the top of our radar… and not without reason. We are officially initiating coverage on Shuttle Pharmaceuticals (Nasdaq: SHPH) —starting right now. A Float This Thin Can Move Fast… One of the first things that stands out? Supply—or rather, the lack of it. As of now, there are fewer than 3.5M shares in (SHPH)’s public float.  That puts it in ultra-low float territory, a space where even modest interest can trigger significant movement simply due to scarcity. And recently?  That scenario has already started to play out.  An approximate 57% move inside of just 6 sessions, from $.3501 on 3/31/2025 to $.55 on 4/7/2025, makes a case for bullish momentum potential. Momentum Beneath the Surface… With a market cap under $2.5M, (SHPH) currently sits in the category of companies that often slip under the radar—until a key moment changes that. For (SHPH), several of those moments are now stacking up. The company recently announced a milestone in patient enrollment for its Phase 2 trial of Ropidoxuridine, a radiation sensitizer being tested for use in patients with glioblastoma, an aggressive and highly challenging form of brain cancer. This development aligns with the broader industry trend: the global glioblastoma multiforme (GBM) treatment market is projected to grow from $2.48B in 2024 to $2.74B in 2025, reflecting a compound annual growth rate (CAGR) of 10.2%. ​ As of the last update, 40% of the targeted patients in the randomized portion of the study have been enrolled.  Clinical sites include major research centers like Georgetown University Medical Center and University of Virginia Cancer Center. This development is especially timely. The global glioblastoma treatment space is entering a new phase, as limitations of traditional options like surgery, radiation, and chemotherapy continue to spark growing interest in more targeted and innovative approaches. Recurrent cases are on the rise, and each year, more than 200,000 new glioma diagnoses are reported globally—a trend that underscores the need for more effective solutions. Looking ahead, the global glioblastoma multiforme (GBM) treatment market is projected to exceed $3B in 2025—and may approach $5.68B by 2033, reflecting growth of nearly 89% driven by advancements in personalized medicine, immunotherapy, and novel treatment platforms. More Than One Shot on Goal… (SHPH)’s pipeline doesn’t stop at one product. They’re also advancing SP-2-225, a selective HDAC6 inhibitor being developed to enhance immune system responses in combination with radiation therapy.  Early-stage research suggests this approach may be able to trigger systemic immune activity—not just local control.  Meanwhile, they’re developing diagnostic tools like: PC-RAD, a blood-based test for assessing radiation therapy outcomes in prostate cancer PSMA-B, a dual-use molecule that could be used for both imaging and treatment of metastatic disease A recent collaboration with UCSF (University of California, San Francisco) is helping accelerate development of PSMA-B. Leadership Shifts and Fresh Capital… In March 2025, (SHPH) announced the appointment of Christopher Cooper as interim Co-CEO.  His role?  Support the next phase of the company’s expansion and corporate visibility.  Cooper brings over 27 years of experience working with public and private firms. Shortly after, the company completed a $5.75M underwritten offering, bringing in additional funding to support its pipeline and future activities. The Gaithersburg Advantage… (SHPH) didn’t end up in Maryland by accident.  This region: Has one of the highest concentrations of STEM professionals in the U.S. Anchors a $17B life sciences industry with an innovation-first culture Offers close access to NIH and FDA, enabling smoother regulatory and clinical collaboration This isn’t just about one company—it’s about being in the right place, with the right people, working on real-world solutions. Bottom Line… There’s a reason this company landed on our radar. Between its lean float, recent clinical progress, added leadership depth, and new capital, (SHPH) may be entering a phase where under-the-surface developments begin catching wider attention. We have officially announced coverage on (SHPH) and have it at the top of our watchlist right now—you may want to do the same. 7 Reasons Why (SHPH) Just Shot To The Top Of Radar… 1. Ultra-Low Float: With less than 3.5M shares circulating in the public float, even a modest shift in demand could lead to the potential for significant swings—especially in a setup like (SHPH)'s. 2. Recent Market Recognition: From $0.3501 on March 31 to $0.55 by April 7, (SHPH) has already demonstrated how thin supply can translate into sharp upside when interest begins to build. 3. Growing Global Market: The glioblastoma treatment space is projected to exceed $3B in 2025—and may reach around $5.68B by 2033, aligning with (SHPH)’s ongoing work in this space. 4. Advancing a Phase 2 Trial: The company recently hit a milestone in its Phase 2 trial of Ropidoxuridine, aimed at improving radiation response in glioblastoma patients—a high-need area of oncology that (SHPH) is actively addressing. 5. Multiple Programs in Development: Beyond its lead candidate, (SHPH) is advancing a selective HDAC6 inhibitor and developing diagnostic tools like PC-RAD and PSMA-B, with academic collaboration underway at UCSF. 6. New Leadership and Capital: In March 2025, a new interim Co-CEO with 27+ years of experience was appointed, and shortly after, (SHPH) closed a $5.75M underwritten offering to fund upcoming developments. 7. Strategic Biotech Hub Location: Based in Gaithersburg, Maryland—home to over 200 biotech firms and near the NIH and FDA—(SHPH) benefits from a location built for innovation, research access, and regulatory proximity. Pull Up (SHPH) And Take A Look… With multiple catalysts now in play—from clinical progress and pipeline depth to recent leadership changes and a capital infusion— Shuttle Pharmaceuticals (Nasdaq: SHPH) has positioned itself as a name worth watching closely. Its ultra-low float, recent chart action, and presence in a high-growth medical segment backed by a multibillion-dollar global forecast only add to the case for closer inspection. We will have all eyes on (SHPH) right now.  Consider taking a look at (SHPH) this morning.  (SHPH) surpassed several key moving averages on its approximately 35% overnight move from $.40 to $.54 this morning’s early session, including its 5-Day, 20-Day, and 50-Day.  My next update could be out shortly—keep an eye on your inbox and mobile device. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between TD Media LLC and IR Agency LLC, TD Media LLC has been hired for a period beginning on 04/10/2025 and ending on 04/11/2025 to publicly disseminate information about (SHPH:US) via digital communications. Under this agreement, TD Media LLC has been paid one hundred thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (SHPH:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/shph/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice